Research programme: DNA vaccines - CytoGenix

Drug Profile

Research programme: DNA vaccines - CytoGenix

Alternative Names: CYDBA 507; Ebola virus DNA vaccine - CytoGenix; H5N1 influenza virus vaccine - CytoGenix; HIV DNA vaccine - CytoGenix; Influenza A virus DNA vaccine H5N1 - CytoGenix; Multivalent DNA vaccine against H5N1 - CytoGenix; Pandemic flu DNA vaccine - CytoGenix; Seasonal flu DNA vaccine - CytoGenix; Smallpox DNA vaccine - CytoGenix

Latest Information Update: 15 Sep 2010

Price : $50

At a glance

  • Originator CytoGenix
  • Developer CytoGenix; United States Army Medical Research Institute of Infectious Diseases
  • Class DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Ebola virus infections; HIV infections; Influenza A virus H5N1 subtype; Influenza virus infections; Smallpox

Most Recent Events

  • 04 Jul 2008 Preclinical development is ongoing
  • 13 Sep 2007 Preclinical development is ongoing
  • 18 Oct 2005 Preclinical trials in HIV infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top